MAHON PAUL A 4
4 · UNITED THERAPEUTICS Corp · Filed Mar 19, 2026
Research Summary
AI-generated summary of this filing
United Therapeutics (UTHR) EVP Paul Mahon Exercises Options, Sells Shares
What Happened
- Paul A. Mahon, EVP & General Counsel of United Therapeutics (UTHR), exercised 8,300 stock options at $146.03/share (cost = $1,212,049) on 2026-03-19 and sold the resulting 8,300 shares the same day in multiple open-market trades for total proceeds of about $4,398,611.
- The exercise + sale was executed pursuant to a pre-arranged 10b5‑1 trading plan (entered August 11, 2025). Net cash inflow before fees and taxes is roughly $3.19M (proceeds minus exercise cost).
Key Details
- Date: March 19, 2026
- Option exercise: 8,300 shares at $146.03 ($1,212,049)
- Sales: 8,300 shares sold in multiple trades; per-trade weighted average prices ranged roughly from $527.0 to $533.48; total proceeds ≈ $4,398,611
- Shares owned after transaction: Not specified in the filing
- Footnotes: F1 confirms exercise and sale under a 10b5‑1 plan; F2–F8 note the sales were executed in multiple trades with reported weighted-average prices and that the reporting person will provide full trade-level details on request
- Timeliness: Filing date and report period are both 2026-03-19 — appears timely (not late)
- Transaction codes: M = option exercise/conversion; S = open-market sale
Context
- This was an option exercise immediately followed by sale under a 10b5‑1 plan (effectively a planned, routine monetization of equity rather than an open-market purchase). Such transactions are common for executives exercising compensation-related options and do not by themselves indicate a change in company outlook.
Insider Transaction Report
Form 4
MAHON PAUL A
EVP & GENERAL COUNSEL
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-03-19$146.03/sh+8,300$1,212,049→ 53,472 total - Sale
Common Stock
[F1][F2]2026-03-19$527.47/sh−753$397,184→ 52,719 total - Sale
Common Stock
[F1][F3]2026-03-19$528.41/sh−1,439$760,382→ 51,280 total - Sale
Common Stock
[F1][F4]2026-03-19$529.82/sh−2,808$1,487,733→ 48,472 total - Sale
Common Stock
[F1][F5]2026-03-19$530.63/sh−1,776$942,407→ 46,696 total - Sale
Common Stock
[F1][F6]2026-03-19$531.62/sh−794$422,109→ 45,902 total - Sale
Common Stock
[F1][F7]2026-03-19$532.50/sh−650$346,124→ 45,252 total - Sale
Common Stock
[F1][F8]2026-03-19$533.41/sh−80$42,672→ 45,172 total - Exercise/Conversion
Stock Option
[F1]2026-03-19−8,300→ 25,200 totalExercise: $146.03From: 2020-03-15Exp: 2027-03-15→ Common Stock (8,300 underlying)
Footnotes (8)
- [F1]This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
- [F2]This transaction was executed in multiple trades at prices ranging from $526.99 to $527.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $528.035 to $529.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This transaction was executed in multiple trades at prices ranging from $529.10 to $530.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F5]This transaction was executed in multiple trades at prices ranging from $530.11 to $531.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F6]This transaction was executed in multiple trades at prices ranging from $531.17 to $532.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F7]This transaction was executed in multiple trades at prices ranging from $532.19 to $532.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F8]This transaction was executed in multiple trades at prices ranging from $533.34 to $533.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Signature
/s/ John S. Hess, Jr. under Power of Attorney|2026-03-19